To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Prometheus Biosciences, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Prometheus Biosciences, Inc. (“Prometheus” or the “Company”) (NASDAQ: RXDX), in connection with its acquisition by Merck & Co., Inc. (NYSE: MRK).  Under the merger agreement, Prometheus shareholders will receive $200.00 cash per share.  The transaction value is approximately $10.8 billion.

Weiss Law is investigating whether (i) Prometheus’ board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the per share merger consideration adequately compensates Prometheus’ shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.